LC
APTO

Lindbrook Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Lindbrook Capital’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed -$12K – 2023
2021
Q1 		$12K Buy
+4
New +$7.93K ﹤0.01% 963
2020
Q3 		– Sell
-2
Closed -$6K – 1877
2020
Q2 		$6K Sell
2
-5
-71% -$16.1K ﹤0.01% 1054
2020
Q1 		$18K Buy
+7
New +$20.9K 0.01% 587

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Lindbrook Capital's APTO Position: Q2 2021 in Review

Lindbrook Capital sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 4 shares — an estimated $12K sold.

Lindbrook Capital first reported a position in APTO in Q1 2020 and held it in 3 quarters. The position peaked at $18K in Q1 2020. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Lindbrook Capital reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Lindbrook Capital sold 4 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $12K.
  • Lindbrook Capital first reported a position in Aptose Biosciences, Inc. in Q1 2020 and held it in 3 quarters.
  • Lindbrook Capital's Aptose Biosciences, Inc. position peaked at $18K in Q1 2020.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Lindbrook Capital's 13F filing for Q2 2021, filed 27 Jul 2021.